{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:26:43Z","timestamp":1777904803116,"version":"3.51.4"},"reference-count":48,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.271543","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:55:21Z","timestamp":1772124921000},"page":"758-764","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of [\n                    <sup>177<\/sup>\n                    Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Malick","family":"Bio Idrissou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Aguiar Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansel","family":"Comas Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liudmila H.","family":"Lambert Lepesevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadira","family":"Medina-Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres F.","family":"Mejia Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Massey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Carston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Munson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026050105301230000_67.5.758.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026050105301230000_67.5.758.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"2026050105301230000_67.5.758.3","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol."},{"key":"2026050105301230000_67.5.758.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.10.001"},{"key":"2026050105301230000_67.5.758.5","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.10167"},{"key":"2026050105301230000_67.5.758.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.034"},{"key":"2026050105301230000_67.5.758.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.12.019"},{"key":"2026050105301230000_67.5.758.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0073-9"},{"key":"2026050105301230000_67.5.758.9","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301230000_67.5.758.10","first-page":"2321","article-title":"Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization","volume":"57","author":"Kawakami","year":"1997","journal-title":"Cancer Res."},{"key":"2026050105301230000_67.5.758.11","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2026050105301230000_67.5.758.12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status","volume":"5","author":"L\u00fctje","year":"2015","journal-title":"Theranostics."},{"key":"2026050105301230000_67.5.758.13","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2026050105301230000_67.5.758.14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026050105301230000_67.5.758.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026050105301230000_67.5.758.16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00259-019-04584-1","article-title":"Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks","volume":"47","author":"Rasul","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301230000_67.5.758.17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026050105301230000_67.5.758.18","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.43.4.244"},{"key":"2026050105301230000_67.5.758.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266141"},{"key":"2026050105301230000_67.5.758.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026050105301230000_67.5.758.21","doi-asserted-by":"publisher","DOI":"10.7150\/thno.18719"},{"key":"2026050105301230000_67.5.758.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188722"},{"key":"2026050105301230000_67.5.758.23","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharm."},{"key":"2026050105301230000_67.5.758.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05837-2"},{"key":"2026050105301230000_67.5.758.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223479"},{"key":"2026050105301230000_67.5.758.26","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1021\/acs.molpharmaceut.8b00602","article-title":"Molar activity of Ga-68 labeled PSMA inhibitor conjugates determines PET imaging results","volume":"15","author":"Wurzer","year":"2018","journal-title":"Mol Pharm."},{"key":"2026050105301230000_67.5.758.27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics."},{"key":"2026050105301230000_67.5.758.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147181"},{"key":"2026050105301230000_67.5.758.29","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/acs.molpharmaceut.0c00199","article-title":"Combined application of albumin-binding [177 Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics","volume":"17","author":"Borgna","year":"2020","journal-title":"Mol Pharm."},{"key":"2026050105301230000_67.5.758.30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026050105301230000_67.5.758.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.02.007"},{"key":"2026050105301230000_67.5.758.32","first-page":"807","article-title":"Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production","volume":"47","author":"Uusij\u00e4rvi","year":"2006","journal-title":"J Nucl Med."},{"key":"2026050105301230000_67.5.758.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170423"},{"key":"2026050105301230000_67.5.758.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265524"},{"key":"2026050105301230000_67.5.758.35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026050105301230000_67.5.758.36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-022-00181-0","article-title":"Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC\/HPLC analysis, demonstrated by [177Lu]Lu-PSMA","volume":"7","author":"Hooijman","year":"2022","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026050105301230000_67.5.758.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05057-6"},{"key":"2026050105301230000_67.5.758.38","doi-asserted-by":"crossref","first-page":"1221103","DOI":"10.3389\/fonc.2023.1221103","article-title":"177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Front Oncol."},{"key":"2026050105301230000_67.5.758.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04434-0"},{"key":"2026050105301230000_67.5.758.40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-018-0386-4","article-title":"External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies","volume":"8","author":"Kurth","year":"2018","journal-title":"EJNMMI Res."},{"key":"2026050105301230000_67.5.758.41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther."},{"key":"2026050105301230000_67.5.758.42","first-page":"850","article-title":"Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J Nucl Med."},{"key":"2026050105301230000_67.5.758.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"},{"key":"2026050105301230000_67.5.758.44","doi-asserted-by":"crossref","unstructured":"Normal Tissue Radiation Responses. In: Chang DS Lasley FD Das IJ Mendonca MS Dynlacht JR , eds. Basic Radiotherapy Physics and Biology. Springer International Publishing; 2014:265\u2013275.","DOI":"10.1007\/978-3-319-06841-1_26"},{"key":"2026050105301230000_67.5.758.45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.5306\/wjco.v12.i12.1101","article-title":"Liver regeneration biology: implications for liver tumour therapies","volume":"12","author":"Hadjittofi","year":"2021","journal-title":"World J Clin Oncol."},{"key":"2026050105301230000_67.5.758.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2005.04.005"},{"key":"2026050105301230000_67.5.758.47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-025-00333-y","article-title":"Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model","volume":"10","author":"Vilangattil","year":"2025","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026050105301230000_67.5.758.48","first-page":"284","article-title":"Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents","volume":"35","author":"Roy","year":"2020","journal-title":"Cancer Biother Radiopharm."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:30:42Z","timestamp":1777638642000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.271543"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271543","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}